Shares of Moderna (MRNA) rose by a staggering 38.75% in 30 days from $156.4 to $217.00 at 21:14 EST on Thursday, following the last session’s upward trend. NASDAQ Composite (MRNA) is jumping 0.78% to $14,020.33, following the last session’s upward trend,
Moderna’s last close was $217.44, 4.51% under its 52-week high of $227.71.
Today’s last reported volume for Moderna is 11602903 which is 23.33% above its average volume of 9408237.
Moderna’s sales growth is 6546% for the ongoing quarter and 7125.9% for the next. The company’s growth estimates for the current quarter and the next is 2100% and 1428.8%, respectively.
Year-on-year quarterly revenue growth grew by 3960.8%, now sitting on 803.4M for the twelve trailing months.
Moderna’s last week, last month’s, and last quarter’s current volatility was 2.83%, 1.03%, and 3.60%, respectively.
Moderna’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.83% (last week), 2.58% (last month), and 3.60% (last quarter), respectively.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $217.00 at 21:14 EST, below its 52-week high of $227.71 and way above its 52-week low of $54.21.
Moderna’s Moving Average
Moderna’s value is way above its 50-day moving average of $175.41 and way above its 200-day moving average of $151.06.
Previous days news about Moderna (MRNA)
Moderna talking to U.S. about shots for low-income countries. According to Bloomberg Quint on Wednesday, 9 June, "Both the Moderna and the Pfizer vaccines require two doses given several weeks apart to provide maximum protection from the coronavirus."
Moderna files for clearance of covid vaccine in adolescents. According to Bloomberg Quint on Thursday, 10 June, "The submission to the FDA is based on data from adolescents 12 through 17 years old, Moderna said. "
More news about Moderna (MRNA).